

BÖLÜM 15

ÖZEL YAŞ GRUPLARINDA MEME KANSERİ YÖNETİMİ

Hüseyin Özgür AYTAÇ¹

GİRİŞ

Günümüzde artan erken tanı olanakları ve giderek bireyselleşmekte olan meme kanseri tedavisi, genç yaşta konulan tanıların her geçen gün artıyor olması ve ileri yaş hastalarda ise tedavi basamaklarından sakınma eğilimindeki artış, bu iki yaş grubunu, genç ve ileri yaş hastaları daha farklı değerlendirmeyi gerekli kılmaktadır. Bu bölümde, genç ve ileri yaş hastalarının meme kanseri yönetimi ele alınmıştır.

GENÇ ERİŞKİNDE MEME KANSERİ

Meme kanseri yönetiminde birçok nedenden ötürü genç meme kanserlerinin yeri ayrıcalıklıdır. Bugün pek çok kılavuzun ortak görüşü 40 yaş altı hastaların genç yaş olarak ele alınması gerektiği şeklindedir. Bilindiği üzere meme kanseri yaşa bağlı bir hastalıktır ve ilerleyen yaşla birlikte görülme sıklığı artar [1]. Örneğin 30-39 yaş arası yıllık meme kanseri insidansı %0,04 iken bu oran 80 yaşına gelindiğinde %10'u aşmaktadır. Diğer bir ifadeyle, bugün için, 60-69 yaşları arasında her 25 kadından biri meme kanserine yakalanmaktayken, bu oran 30-39 yaşları arasında her 65 kadından biri şeklinde olmaktadır. Yani tüm meme kanseri tanılarının yaklaşık yarısını 50-69 yaşları arasındaki hastalar oluştururken, ancak %5 kadarını 40 yaş altındaki ve sadece %2,5 kadarını 35 yaş altındaki hastalar oluşturmaktadır [2-5]. Bu genç yaş grubu tüm meme kanserleri içinde az yer tutuyor olmasından ötürü çoğu kez klinik değerlendirmede hak ettiği farklı ve titiz

¹ Doç. Dr., Başkent Üniversitesi Tıp Fakültesi Genel Cerrahi AD., oaytac@gmail.com

KAYNAKLAR

1. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z: SEER cancer statistics review, 1975–2012. National Cancer Institute 2014.
2. Society AC: Breast cancer facts & figures 2019–2020. Am Cancer Soc 2019:1-44.
3. Greif JM: Mammographic screening for breast cancer: An invited review of the benefits and costs. *The Breast* 2010, 19(4):268-272.
4. Anderson WF, Jatoi I, Sherman ME: Qualitative age interactions in breast cancer studies: mind the gap. *Journal of Clinical Oncology* 2009, 27(32):5308.
5. Pollán M: Epidemiology of breast cancer in young women. *Breast cancer research and treatment* 2010, 123(1):3-6.
6. Kalager M, Zelen M, Langmark F, Adami H-O: Effect of screening mammography on breast-cancer mortality in Norway. *New England Journal of Medicine* 2010, 363(13):1203-1210.
7. Network NCC: NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022. In.
8. McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ: Effects of age on the detection and management of breast cancer. *Cancers* 2015, 7(2):908-929.
9. Osako T, Iwase T, Takahashi K, Iijima K, Miyagi Y, Nishimura S, Tada K, Makita M, Akiyama F, Sakamoto G: Diagnostic mammography and ultrasonography for palpable and nonpalpable breast cancer in women aged 30 to 39 years. *Breast cancer* 2007, 14(3):255-259.
10. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. *Journal of the American College of surgeons* 2009, 208(3):341-347.
11. Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ: US breast cancer mortality trends in young women according to race. *Cancer* 2015, 121(9):1469-1476.
12. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. *Journal of clinical oncology* 2008, 26(20):3324-3330.
13. Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G: Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study. *Journal of the national cancer institute* 2013, 105(13):978-988.
14. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A: PD-L1 expression in triple-negative breast cancer. *Cancer immunology research* 2014, 2(4):361-370.
15. Rosenberg SM, Partridge AH: Management of breast cancer in very young women. *The Breast* 2015, 24:S154-S158.
16. Cancer CGoHFib: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *The Lancet* 2001, 358(9291):1389-1399.
17. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpfer KL, Scholl T, Tavtigian SV, Pruss DR: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *Journal of Clinical Oncology* 2002, 20(6):1480-1490.
18. McGuire KP, Mamounas EP: Management of hereditary breast cancer: ASCO, ASTRO, and SSO guideline. *Annals of Surgical Oncology* 2020, 27(6):1721-1723.
19. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S: The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. *European journal of cancer* 2012,

48(18):3355-3377.

20. Doherty J, Bonadies DC, Matloff ET: Testing for hereditary breast cancer: panel or targeted testing? Experience from a clinical cancer genetics practice. *Journal of genetic counseling* 2015, 24(4):683-687.
21. Barry M, Kell M: Radiotherapy and breast reconstruction: a meta-analysis. *Breast cancer research and treatment* 2011, 127(1):15-22.
22. Ho AY, Hu ZI, Mehrara BJ, Wilkins EG: Radiotherapy in the setting of breast reconstruction: types, techniques, and timing. *The Lancet Oncology* 2017, 18(12):e742-e753.
23. Jaggi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, Pusic AL, Wilkins EG: Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. *JNCI: Journal of the National Cancer Institute* 2018, 110(2):157-165.
24. Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RdNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MdP: Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). *Familial Cancer* 2020, 19(1):47-53.
25. Lazzari G, Buono G, Zannino B, Silvano G: Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues? *Breast Cancer: Targets and Therapy* 2021, 13:299.
26. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL: The role of BRCA mutation testing in determining breast cancer therapy. *Nature reviews Clinical oncology* 2010, 7(12):708-717.
27. McCann KE, Hurvitz SA: Advances in the use of PARP inhibitor therapy for breast cancer. *Drugs in context* 2018, 7.
28. Ozyigit G, Gultekin M: Current role of modern radiotherapy techniques in the management of breast cancer. *World journal of clinical oncology* 2014, 5(3):425.
29. Kurtz J: The curative role of radiotherapy in the treatment of operable breast cancer. *European Journal of Cancer* 2002, 38(15):1961-1974.
30. Winters ZE, Benson JR, Pusic AL: A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life. *Annals of surgery* 2010, 252(6):929-942.
31. Heneghan H, Prichard R, Lyons R, Regan P, Kelly J, Malone C, McLaughlin R, Sweeney K, Kerin M: Quality of life after immediate breast reconstruction and skin-sparing mastectomy—a comparison with patients undergoing breast conserving surgery. *European Journal of Surgical Oncology (EJSO)* 2011, 37(11):937-943.
32. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, Melbye M: Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. *Cancer* 2004, 100(4):688-693.
33. Frandsen J, Ly D, Cannon G, Suneja G, Matsen C, Gaffney DK, Wright M, Kokeny KE, Poppe MM: In the modern treatment era, is breast conservation equivalent to mastectomy in women younger than 40 years of age? A multi-institution study. *International Journal of Radiation Oncology* Biology* Physics* 2015, 93(5):1096-1103.
34. Heemskerck-Gerritsen BA, Jager A, Koppert LB, Obdeijn A, Collée M, Meijers-Heijboer HE, Jenner DJ, Oldenburg HS, van Engelen K, de Vries J: Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. *Breast cancer research and treatment* 2019, 177(3):723-733.
35. Heemskerck-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers-Heijboer HE: Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *International journal of cancer* 2015, 136(3):668-677.
36. Ingham SL, Sperrin M, Baidam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DGR: Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at

- time of family referral. *Breast cancer research and treatment* 2013, 142(3):611-618.
37. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV: American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. *Annals of surgical oncology* 2012, 19(10):3144-3151.
 38. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijn JH, Orzalesi L: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *The lancet oncology* 2014, 15(12):1303-1310.
 39. van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJ, Siesling S: 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. *The Lancet Oncology* 2016, 17(8):1158-1170.
 40. Correa C, Harris EE, Leonard MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR: Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. *Practical radiation oncology* 2017, 7(2):73-79.
 41. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Horst K, Moran J: Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. *Practical radiation oncology* 2018, 8(3):145-152.
 42. Group EBCTC: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *The Lancet* 2005, 365(9472):1687-1717.
 43. De Laurentiis M, Canello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. In: *Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]*. edn.: Centre for Reviews and Dissemination (UK); 2008.
 44. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD: Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: Results from a herceptin adjuvant trial. *Journal of clinical oncology* 2013, 31(21):2692-2698.
 45. Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA: Managing breast cancer in younger women: challenges and solutions. *Breast Cancer: Targets and Therapy* 2016, 8:1.
 46. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *The Lancet* 2013, 381(9869):805-816.
 47. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ: Adjuvant ovarian suppression in premenopausal breast cancer. *New England Journal of Medicine* 2015, 372(5):436-446.
 48. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer Jr CE, Dees EC, Goetz MP: Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. *New England Journal of Medicine* 2019, 380(25):2395-2405.
 49. Piccart M, van't Veer LJ, Poncet C, Cardozo JML, Delaloge S, Pierga J-Y, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA: 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. *The Lancet Oncology* 2021, 22(4):476-488.
 50. Hery C, Ferlay J, Boniol M, Autier P: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. *Annals of Oncology* 2008, 19(6):1187-1194.
 51. Ries LAG, Young Jr JL, Keel GE, Eisner MP, Lin YD, Horner M-JD: Cancer survival among

- adults: US SEER program, 1988–2001. Patient and tumor characteristics SEER Survival Monograph Publication 2007, 7:6215.
52. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanz E: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. *The lancet oncology* 2014, 15(1):23-34.
 53. Markopoulos C, van de Water W: Older patients with breast cancer: is there bias in the treatment they receive? *Therapeutic Advances in Medical Oncology* 2012, 4(6):321-327.
 54. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. *Annals of internal medicine* 1994, 120(2):104-110.
 55. de Glas NA, de Craen AJ, Bastiaannet E, Op't Land EG, Kiderlen M, van de Water W, Siesling S, Portielje JE, Schuttevaer HM, de Bock GTH: Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. *Bmj* 2014, 349.
 56. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. *JNCI: Journal of the National Cancer Institute* 2000, 92(7):550-556.
 57. Lawrence G, Kearins O, Lagord C, Cheung S, Sidhu J, Sagar C: The second all breast cancer report. Focussing on inequalities: variation in breast cancer outcomes with age and deprivation National Cancer Intelligence Network, London 2011.
 58. Aapro M, Wildiers H: Triple-negative breast cancer in the older population. *Annals of oncology* 2012, 23:vi52-vi55.
 59. Wyld L, Garg D, Kumar I, Brown H, Reed M: Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. *British journal of cancer* 2004, 90(8):1486-1491.
 60. Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K, Reed M, Wyld L: Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. *Journal of British Surgery* 2015, 102(9):1056-1063.
 61. Reed M, Audisio R, Wyld L: The role of surgery in the treatment of older women with breast cancer. *Clinical Oncology* 2009, 21(2):103-110.
 62. Kaur P, Santillan AA, McGuire K, Turaga KK, Shamehdi C, Meade T, Ramos D, Mathias M, Parbhoo J, Davis M: The surgical treatment of breast cancer in the elderly: a single institution comparative review of 5235 patients with 1028 patients \geq 70 years. *The Breast Journal* 2012, 18(5):428-435.
 63. Caretta-Weyer H, Greenberg CG, Wilke LG, Weiss J, LoConte NK, Decker M, Steffens NM, Smith MA, Neuman HB: Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis. *Annals of surgical oncology* 2013, 20(13):4145-4152.
 64. Rutgers EJ, Donker M, Straver ME, Meijnen P, Van De Velde CJ, Mansel RE, Westenberg H, Orzalesi L, Bouma WH, Van der Mijle H: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023). In: *American Society of Clinical Oncology*; 2013.
 65. Cortina CS: De-Escalation of Local-Regional Therapy for Older Breast Cancer Patients. *Current Breast Cancer Reports* 2020, 12(4):344-350.
 66. Sun J, Loftus LS, Lee MC: ASO Author Reflections: The De-Escalation of Sentinel Node Biopsy for Breast Cancer. *Annals of Surgical Oncology* 2020, 27(3):838-839.
 67. Christian N, Heelan Gladden A, Friedman C, Gleisner-Patton A, Murphy C, Kounalakis N, Ahrendt G: Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer. *The Breast Journal* 2020, 26(2):133-138.
 68. Thompson J, Le J, Hop A, Melnik M, Paulson J, Wright GP: Impact of Choosing Wisely recommendations on sentinel lymph node biopsy and postoperative radiation rates in women over age 70 years with hormone-positive breast cancer. *Annals of Surgical Oncology* 2021, 28(10):5716-5722.

69. Laporta R, Sorotos M, Longo B, di Pompeo FS: Breast reconstruction in elderly patients: risk factors, clinical outcomes, and aesthetic results. *Journal of Reconstructive Microsurgery* 2017, 33(04):257-267.
70. Maruccia M, Di Taranto G, Onesti MG: One-stage muscle-sparing breast reconstruction in elderly patients: a new tool for retaining excellent quality of life. *The Breast Journal* 2018, 24(2):180-183.
71. Group EBCTC: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *The lancet* 2011, 378(9793):771-784.
72. Powell DE, Cochrane RA, Davie MW: Does anastrozole affect bone resorption similarly in early and late postmenopausal women? *Calcified tissue international* 2011, 88(3):223-230.
73. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R: Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. *Journal of clinical oncology* 2010, 28(6):967-975.
74. Markopoulos C, Tzoracoleftherakis E, Koukouras D, Venizelos B, Zobolas V, Misitzi J, Xepapadakis G, Gogas H: Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. *Journal of cancer research and clinical oncology* 2012, 138(9):1569-1577.
75. Aapro M, Tjulandin S, Bhar P, Gradishar W: Weekly nab-paclitaxel is safe and effective in ≥ 65 years old patients with metastatic breast cancer: a post-hoc analysis. *The Breast* 2011, 20(5):468-474.
76. von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J: A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). *Cancer* 2015, 121(20):3639-3648.
77. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM: Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *The Lancet Oncology* 2015, 16(3):266-273.
78. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. *New England Journal of Medicine* 2004, 351(10):971-977.